• References (0)
  • Citations (1)
Cited By1
Published on May 15, 2019in Critical Reviews in Clinical Laboratory Sciences4.82
Amanda Ricciuto3
Estimated H-index: 3
(U of T: University of Toronto),
Anne M. Griffiths78
Estimated H-index: 78
(U of T: University of Toronto)
AbstractInflammatory bowel disease (IBD) denotes a group of chronic incurable disorders characterized by relapsing-remitting inflammation of the gastrointestinal tract. IBD represents a growing global burden with a prevalence exceeding 0.3% in the Western world and an accelerating incidence in newly industrialized countries. The target for treating IBD has shifted in recent years from symptom control to mucosal healing (MH), which has been shown to be associated with favorable long-term outcomes...
Published on Jun 3, 2019in Expert Review of Clinical Immunology3.91
Jun Kato (Memorial Hospital of South Bend), Takeichi Yoshida (Wakayama Medical University), Sakiko Hiraoka14
Estimated H-index: 14
(Okayama University)
ABSTRACTIntroduction: Prediction of treatment outcome and clinical relapse in patients with inflammatory bowel disease (IBD), either ulcerative colitis (UC) or Crohn’s disease (CD), is particularly important because therapeutics for IBD are not always effective and patients in remission could frequently relapse. Because undergoing endoscopy for the purpose is sometimes invasive and burdensome to patients, the performance of surrogate biomarkers has been investigated.Areas covered: We particularl...
View next paperLevels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn’s Disease